Phaseline

Targets › KMT2A

KMT2A (Histone-lysine N-methyltransferase 2A): drug programs, companies and trials

3 programs from 3 companies in 15 trials: 11 Phase 1, 2 Phase 3, 2 Phase 2; Oncology; next expected readout Dec 2026.

Histone methyltransferase that plays an essential role in early development and hematopoiesis. Catalytic subunit of the MLL1/MLL complex, a multiprotein complex that mediates both methylation of 'Lys-4' of histone H3 (H3K4me) complex and acetylation of 'Lys-16' of histone H4 (H4K16ac). (UniProt, Q03164)

Open in Phaseline: the race on KMT2A, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Syndax Pharmaceuticalsrevumenib
Menin/Histone-lysine N-methyltransferase MLL inhibitor; Menin inhibitor
MEN1, KMT2APhase 3Acute Myeloid Leukemias; Acute Myeloid Leukemia; Acute Myeloid Leukemia, Adult; Recurrent Acute Leukemia of Ambiguous Lineage …Feb 2027
M.D. Anderson Cancer CenterRevumenib Sesquifumarate (SNDX-5613)
Menin/Histone-lysine N-methyltransferase MLL inhibitor
MEN1, KMT2APhase 2Leukemia; Acute Myeloid LeukemiaDec 2026
The First Affiliated Hospital of Soochow UniversityBY002
Menin inhibitor targeting KMT2A-rearranged and NPM1-mutant acute leukemia
KMT2A, MENINPhase 1Acute LeukemiaMar 2027

Conditions

Acute Myeloid Leukemia (5) Acute Myeloid Leukemias (2) Acute Leukemia (2) Leukemia (2) Acute Myeloid Leukemia, Adult (1) Recurrent Acute Leukemia of Ambiguous Lineage (1) Refractory Acute Myeloid Leukemia (1) Acute Myeloid Leukemia With FLT3/ITD Mutation (1)

Modalities

small molecule (3)

Companies

Syndax Pharmaceuticals (1) M.D. Anderson Cancer Center (1) The First Affiliated Hospital of Soochow University (1)

Related targets

MEN1 (2) MENIN (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.